Inhaling Hypertonic Saline Decreases Hospital Admissions In Children With Bronchiolitis
Article ID: 618311
Released: 22-May-2014 3:05 PM EDT
Source Newsroom: Children's Hospital Los Angeles Saban Research Institute
Newswise — A team of researchers, led by physicians from Children’s Hospital Los Angeles, have found that infants with bronchiolitis who were treated with inhaled hypertonic saline in the emergency department (ED) were less likely to require admission to the hospital compared to infants treated with normal saline.
The study, conducted at Children’s Hospital Los Angeles and UCSF Benioff Children’s Hospital Oakland, will be published in JAMA Pediatrics on May 26.
Bronchiolitis is a respiratory infection common in infants and young children that results in approximately 150,000 hospitalizations each year, with an estimated cost of $500 million.
“Previous studies have shown positive effects of using hypertonic saline, a concentrated salt solution, on infants and young children with bronchiolitis,” said lead author, Susan Wu, MD, with The Saban Research Institute of Children’s Hospital Los Angeles. “What is unique about this study is that we looked at the effect of administering hypertonic saline in the ED and then considered its effect on hospital admission.”
The investigators treated 408 babies and young children; 197 received normal saline and 211 received 3% hypertonic saline. Patients were treated with their assigned intervention up to three times in the ED. Those admitted continued to receive the therapy every eight hours until discharge.
Investigators found that 42.6% of patients treated with normal saline required hospital admission compared with 28.9% of patients treated with hypertonic saline.
“We found that infants and young children with bronchiolitis treated with nebulized hypertonic saline in the ED were less likely to require hospitalization,” said Wu, who is also an assistant professor of Clinical Pediatrics at the Keck School of Medicine of the University of Southern California. “It’s gratifying to find an inexpensive yet effective therapy that helps patients while also reducing the cost of healthcare.”
Co-authors include principal investigator Wilbert H. Mason, MD, MPH, Ara Balkian, MD, MBA, Valerie Mira, MPH, Fasha F. Liley, MD, and Sheree M. Schrager, PhD, MS, of The Saban Research Institute of Children’s Hospital Los Angeles; and Chris Baker, MD, Michael E. Lang, MD, and Carmel Papa, MS-HCA of UCSF Benioff Children’s Hospital Oakland.
This study was supported by a grant from the Thrasher Research Fund and by a Mentored Junior Faculty Career Development Award from the Department of Pediatrics, Keck School of Medicine of the University of Southern California.
About Children’s Hospital Los Angeles Children's Hospital Los Angeles has been named the best children’s hospital in California and among the top five in the nation for clinical excellence with its selection to the prestigious US News & World Report Honor Roll. Children’s Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States, is one of America's premier teaching hospitals and has been affiliated with the Keck School of Medicine of the University of Southern California since 1932.
Media Contact: Ellin Kavanagh, firstname.lastname@example.org(323) 361-8505